Anebulo Pharmaceuticals (ANEB) Enterprise Value (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Enterprise Value of -$9.0 million for Q4 2025, up 39.72% year-over-year from -$6.5 million in Q4 2024, and up 12.68% quarter-over-quarter from -$10.4 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Enterprise Value (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Enterprise Value for 6 consecutive years, with -$9.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 39.72% year-over-year to -$9.0 million; the TTM figure through Dec 2025 stood at -$9.0 million (up 39.72% YoY), while the FY2025 annual figure was -$11.6 million, down 275.8% from the prior year.
- Enterprise Value grew to -$9.0 million in Q4 2025 per ANEB's latest filing, from -$10.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.4 million in Q3 2024 and bottomed at -$20.0 million in Q2 2021.
- Historically, Enterprise Value has averaged -$11.8 million across 5 years, with a median of -$12.5 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 83.52% — and 2025, when it slumped 637.41%.
- Anebulo Pharmaceuticals' Enterprise Value stood at -$18.0 million in 2021, then grew by 9.18% to -$16.4 million in 2022, then soared by 59.37% to -$6.6 million in 2023, then tumbled by 125.73% to -$15.0 million in 2024, then surged by 39.72% to -$9.0 million in 2025.
- Business Quant data shows ANEB's Enterprise Value at -$9.0 million in Q4 2025, -$10.4 million in Q3 2025, and -$11.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -9.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.04 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Jun 30, 2025 | -11.63 Mn |
| Mar 31, 2025 | -13.28 Mn |
| Dec 31, 2024 | -15.00 Mn |
| Sep 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -3.09 Mn |
| Mar 31, 2024 | -5.15 Mn |
| Dec 31, 2023 | -6.64 Mn |
| Sep 30, 2023 | -8.52 Mn |
| Jun 30, 2023 | -11.25 Mn |
| Mar 31, 2023 | -14.16 Mn |
| Dec 31, 2022 | -16.36 Mn |
| Sep 30, 2022 | -19.21 Mn |
| Jun 30, 2022 | -14.55 Mn |
| Mar 31, 2022 | -16.55 Mn |
| Dec 31, 2021 | -18.01 Mn |
| Sep 30, 2021 | -19.21 Mn |
| Jun 30, 2021 | -19.99 Mn |
| Mar 31, 2021 | -3.31 Mn |